Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug
The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.
Publicis Healthcare Communications Group has hired Kipp Jarecke-Cheng as global chief communications officer.
Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula
Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.
FDA panel says Duchenne drug is not effective; Bill Ackman to appear before Senate committee investigating pricing issues; Daiichi Sankyo to open new headquarters
Verywell.com presents physician-reviewed health and wellness content that aims to be "gentler" than other health websites.
The drugmaker disclosed in its first-quarter earnings report that it is being investigated over ties to nonprofit foundations.
After six years as president of Trio, Renée Wills has joined newly formed agency Kinch.
Valeant names new CEO; Novartis weighs sales of stake in Roche; FDA ad panel to recommend DMD drug
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying
Biogen CEO George Scangos told investors that the company's DTC campaign for Tecfidera was designed to address low awareness for the drug.
Allergan plans sales blitz for Kybella; Novartis U.S. lead steps down; analysts say PCSK9 sales are disappointing so far
IBM Watson Health has publicly announced deals with 18 different companies and patient organizations over the past few years.
The billboards themselves operate on simple principles: fool mosquitoes into thinking they've found a human, and then trap them until they die of dehydration.
Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
Industry is partnering with Watson to try and solve some of healthcare's most pressing questions.
The company said growth in its immunology portfolio offset declining Olysio sales.
Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class
Wieden+Kennedy Portland's VR work for the National Multiple Sclerosis Society lets wheelchair-bound patients experience their favorite activities again, like dancing or surfing.
IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.
He plans to expand the company's consumer health marketing.
Valeant mulls over fire sale; research shows that Opdivo helps advanced melanoma patients survive longer; AstraZeneca considers Medivation
The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.
Already, there's cognitive cooking for your kitchen and cognitive coaching for your daily run. What's Watson's vision for medicine?
The editorial staff of MM&M recently visited IBM Watson's offices in New York. What ensued was the creation of Watson Week.
Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs
The questionnaire gives agencies the opportunity to contribute information to MM&M's definitive Agency A-to-Z directory, which will be published in the July issue.
Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license
With a lead role in IBM Watson's bold gambit to transform healthcare, Kathy McGroddy-Goetz ranks as one of the enterprise's most important individuals.
2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.
Sanofi is reportedly interested in buying Medivation; Sean Parker funds $250 million cancer research institute; FDA will review Merck's allergy biologic
Industry criticism can create opportunities for drugmakers and other healthcare organizations to create a stronger narrative.
The FDA advisory committee voted 12-1 against approving the therapy, citing safety issues and requesting more data.
California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
Analysts have estimated the drug could reach $2 billion in sales in the next four years.
Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review
Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease
Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's
LLNS CEO Sharon Callahan has been named CEO of TBWA/WorldHealth, which is based in New York.
It operates a number of ad agencies, like GSW and Palio, as well as a group of PR firms that includes Chandler Chicco Agency.
The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire
CeyHello, a newly launched social networking mobile app, tackles medication adherence by connecting patients, caregivers and family members.
The drugmaker instead suggested using an economic model it developed.
Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza
The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.
Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data
The drugmaker marketed a co-pay assistance voucher that failed to provide any risk information about its drug Ulesfia.
GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance
The FTC asks for more info about Pfizer-Allergan deal; the FDA loosens guidelines for abortion-inducing drug; startup to deliver Truvada through an app
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center
The Boston-based agency was acquired by Precision Medicine Group in May.
Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.
The healthcare-focused agency network is committed to spending $50,000 over three years to the Future Leaders in Healthcare Fellowship Program.
WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.
The Catholic health system worked with FleishmanHillard and GSD&M to create the integrated campaign touting its partnership with the Department of Veterans Affairs.
Lawmakers call out high price of Xtandi; Novo Nordisk breaks ground in North Carolina; Sanofi poaches top research scientist from AstraZeneca
Insulet's skin-adhesive technology is being used to improve adherence for patients taking biologics.
Experts say DTC spending is a waste; Alder BioPharma's migraine drug meets study goal; sources tell Stat that execs are leaving Verily Life Sciences
The drugmaker launched a three-part video series that uses humor to address prescription drug abuse.
Giant appointed Ben Mallory, who has held creative leadership roles at AstraZeneca, as its new executive creative director.
Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.
Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren't prescribed blood thinners; the FDA issues generic opioid guidance
Valeant hiked price of assisted-suicide drug; Bristol-Myers Squibb acquires autoimmune drugmaker; the FDA approves Teva's asthma drug
Facebook has found that 43% of people who watch the first three seconds of a video will stay for 10 seconds. To create engagement, agencies need to rethink the creative approach.
Anti-DTC measures are unlikely to be enacted even though the backlash itself is a function of political change.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
Propeller Health partners with Boehringer Ingelheim; judge votes in favor of Merck in HCV patent dispute; the FDA approves Eli Lilly's Taltz
There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.
Apple debuts CareKit; Anthem sues Express Scripts; Sanofi reportedly moving out of Paris
The Facebook for doctors launches Pages, allowing healthcare companies to establish a presence on Sermo and engage with physicians.
Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development
AstraZeneca appointed Jennie Younger, who has held senior communications roles at GlaxoSmithKline, Deutsche Bank, and FTI Consulting, as its vice president of global corporate affairs.
OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
Entresto's sales are still lower than expected; GSK CEO Witty to retire in 2017; tech assistants sometimes fail to account for women's health needs
The deadline has been extended to April 8.
A jury ruled in favor of Amgen, saying its patents for Repatha are valid.
CDC issues new opioid prescribing guidelines; Sanofi partnership will focus on oral-drug development; MannKind hires Amgen exec
IBS drug Xifaxan missed the company's sales projection for the fourth quarter of 2015 by $180 million.
Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.
The FDA will prioritize certain generic drug applications; Valeant posts fourth-quarter loss; medical marijuana drug shines in Phase-III trial
The drugmaker promoted three to keep pace with the evolving healthcare landscape.
BMS says docs are prescribing Opdivo more than Keytruda; Valeant reportedly weighed replacing CEO during sick leave; the FDA expands use of Xalkori
The agency plans to collaborate more with the rest of its network, inVentiv Health.
Valeant CEO reportedly tells staffers that the worst is behind them; Sanofi hires chief medical officer from Novartis; PhRMA CEO says pricing debate is misinformed
The VA will cover Gilead HCV drugs for veterans; Valeant settles specialty pharmacy lawsuit; Gleevec's price has dramatically increased since approval
The agency has proposed two studies to investigate the use of superimposed text and the use of animated characters.
Sudler & Hennessey is reorganizing the ways its businesses report to its dual CEOs.
For 2016 MM&M enhanced the program with the addition of several new categories.
Amarin settles with the FDA over off-label promotion suit; mobile apps often share medical information with third parties; drug spending rose 12% in 2014
Gilead Sciences has spent about $100 million on Harvoni ads; Allergan taps Khloé Kardashian for Kybella campaign; Sanofi and Merck end vaccines venture
While it's made great strides, the healthcare industry is still behind in some technology and information safeguards.
The Hall of Femme will honor the most-senior female leaders in the pharmaceutical, medical device and agency sectors of the healthcare industry.
Three drugmakers are making big pushes for their second-line treatments as they eye a massive market with few new prescription drug options.
European regulators launch speedier drug approval process: AbbVie and Boehringer Ingelheim to partner on psoriasis drug; the FDA approves hemophilia B drug
The proposed legislation would forbid drugmakers from writing off advertising as a tax deduction.
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Creative partners should push pharma clients to tell better stories
- Retaining talent: How pharma can compete with Google